Taimed Biologics Stock Cash And Equivalents
| 4147 Stock | TWD 90.10 0.70 0.78% |
TaiMed Biologics fundamentals help investors to digest information that contributes to TaiMed Biologics' financial success or failures. It also enables traders to predict the movement of TaiMed Stock. The fundamental analysis module provides a way to measure TaiMed Biologics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to TaiMed Biologics stock.
TaiMed |
TaiMed Biologics Company Cash And Equivalents Analysis
TaiMed Biologics' Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current TaiMed Biologics Cash And Equivalents | 1.02 B |
Most of TaiMed Biologics' fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, TaiMed Biologics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
| Competition |
In accordance with the recently published financial statements, TaiMed Biologics has 1.02 B in Cash And Equivalents. This is 24.26% higher than that of the Biotechnology sector and 128.13% higher than that of the Health Care industry. The cash and equivalents for all Taiwan stocks is 62.25% higher than that of the company.
TaiMed Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses TaiMed Biologics' direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of TaiMed Biologics could also be used in its relative valuation, which is a method of valuing TaiMed Biologics by comparing valuation metrics of similar companies.TaiMed Biologics is currently under evaluation in cash and equivalents category among its peers.
TaiMed Fundamentals
| Return On Equity | -0.18 | |||
| Return On Asset | -0.062 | |||
| Profit Margin | (1.70) % | |||
| Operating Margin | (1.47) % | |||
| Current Valuation | 17.73 B | |||
| Shares Outstanding | 252.37 M | |||
| Shares Owned By Insiders | 17.27 % | |||
| Shares Owned By Institutions | 21.66 % | |||
| Price To Book | 6.45 X | |||
| Price To Sales | 55.99 X | |||
| Revenue | 413.44 M | |||
| Gross Profit | 177.82 M | |||
| EBITDA | (306.83 M) | |||
| Net Income | (470.93 M) | |||
| Cash And Equivalents | 1.02 B | |||
| Cash Per Share | 4.03 X | |||
| Total Debt | 536 M | |||
| Debt To Equity | 0.20 % | |||
| Current Ratio | 10.64 X | |||
| Book Value Per Share | 10.88 X | |||
| Cash Flow From Operations | (211.28 M) | |||
| Earnings Per Share | (2.36) X | |||
| Target Price | 88.0 | |||
| Number Of Employees | 37 | |||
| Beta | 0.51 | |||
| Market Capitalization | 17.62 B | |||
| Total Asset | 4.61 B | |||
| Z Score | 19.2 | |||
| Net Asset | 4.61 B |
About TaiMed Biologics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze TaiMed Biologics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of TaiMed Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of TaiMed Biologics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectAdditional Tools for TaiMed Stock Analysis
When running TaiMed Biologics' price analysis, check to measure TaiMed Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TaiMed Biologics is operating at the current time. Most of TaiMed Biologics' value examination focuses on studying past and present price action to predict the probability of TaiMed Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TaiMed Biologics' price. Additionally, you may evaluate how the addition of TaiMed Biologics to your portfolios can decrease your overall portfolio volatility.